Alimera Sciences, Inc.
Index- P/E- EPS (ttm)-2.64 Insider Own3.00% Shs Outstand7.00M Perf Week-10.38%
Market Cap11.63M Forward P/E- EPS next Y-0.66 Insider Trans0.00% Shs Float5.62M Perf Month-33.06%
Income-18.40M PEG- EPS next Q-0.34 Inst Own30.60% Short Float / Ratio0.41% / 2.05 Perf Quarter-27.11%
Sales54.10M P/S0.21 EPS this Y36.50% Inst Trans3.43% Short Interest0.02M Perf Half Y-70.61%
Book/sh-5.33 P/B- EPS next Y72.30% ROA-37.00% Target Price6.75 Perf Year-69.17%
Cash/sh0.78 P/C2.11 EPS next 5Y- ROE62.20% 52W Range1.57 - 7.92 Perf YTD-39.48%
Dividend- P/FCF- EPS past 5Y-1.10% ROI5.30% 52W High-79.29% Beta1.42
Dividend %- Quick Ratio0.80 Sales past 5Y11.40% Gross Margin85.50% 52W Low4.46% ATR0.17
Employees145 Current Ratio0.90 Sales Q/Q11.50% Oper. Margin-22.60% RSI (14)30.63 Volatility5.81% 8.33%
OptionableNo Debt/Eq- EPS Q/Q-24.40% Profit Margin-34.10% Rel Volume0.00 Prev Close1.64
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume11.19K Price1.64
Recom2.30 SMA20-18.19% SMA50-31.79% SMA200-63.51% Volume0 Change0.00%
May-28-19Initiated Craig Hallum Buy
Apr-27-17Initiated Rodman & Renshaw Buy $4
Nov-17-14Initiated Summer Street Research Buy $12
Sep-29-14Reiterated Northland Capital Outperform $7 → $10
Oct-28-13Upgrade Cowen Market Perform → Outperform
Oct-08-13Initiated Northland Capital Outperform $5
Nov-14-11Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
Dec-27-10Reiterated Oppenheimer Outperform $16 → $14
Oct-11-10Initiated Rodman & Renshaw Mkt Outperform $13
Jun-02-10Initiated Oppenheimer Outperform $16
Feb-27-23 08:00AM
Feb-22-23 08:00AM
Jan-09-23 08:00AM
Dec-29-22 06:02AM
Dec-08-22 08:00AM
08:00AM Loading…
Nov-29-22 08:00AM
Nov-17-22 03:54PM
Nov-16-22 05:05AM
Nov-14-22 08:55AM
Nov-02-22 08:00AM
Nov-01-22 08:00AM
Oct-20-22 09:40AM
Oct-18-22 09:03AM
Oct-06-22 08:00AM
08:00AM Loading…
Sep-23-22 08:00AM
Sep-20-22 08:00AM
Sep-19-22 09:40AM
Sep-02-22 09:40AM
Aug-31-22 08:48AM
Aug-29-22 08:50AM
Aug-19-22 08:50AM
Aug-17-22 09:40AM
Aug-10-22 08:00AM
Aug-09-22 08:00AM
Aug-05-22 08:50AM
Aug-01-22 09:40AM
Jul-27-22 08:45AM
08:00AM Loading…
Jul-26-22 08:00AM
Jul-22-22 10:34AM
Jul-13-22 08:00AM
Jul-08-22 08:00AM
Jun-24-22 07:10AM
Jun-08-22 08:03AM
Jun-02-22 08:00AM
May-12-22 08:03AM
May-09-22 09:15AM
May-06-22 08:00AM
May-05-22 05:55PM
Apr-28-22 08:30AM
Apr-26-22 07:24AM
Apr-06-22 08:00AM
Mar-31-22 08:15AM
Mar-30-22 05:44AM
Mar-28-22 10:48AM
Mar-02-22 08:00AM
Mar-01-22 08:35AM
Feb-24-22 09:25AM
Feb-23-22 08:00AM
Feb-17-22 08:00AM
Feb-07-22 08:00AM
Feb-04-22 08:00AM
Jan-28-22 10:07AM
Jan-05-22 08:00AM
Dec-01-21 07:30AM
Nov-09-21 01:16PM
Nov-06-21 08:15AM
Nov-05-21 10:03AM
Oct-28-21 06:01PM
Oct-21-21 08:00AM
Oct-20-21 03:02PM
Oct-13-21 08:00AM
Sep-02-21 04:30PM
Aug-24-21 08:00AM
Aug-13-21 12:00PM
Aug-10-21 08:00AM
Aug-09-21 08:00AM
Jul-28-21 03:03PM
Jun-05-21 04:22AM
May-27-21 07:15PM
May-17-21 08:12AM
Apr-29-21 03:30PM
Apr-28-21 07:25PM
Apr-26-21 10:51AM
Apr-22-21 08:00AM
Apr-14-21 10:34AM
Apr-09-21 08:00AM
Mar-18-21 08:00AM
Mar-17-21 08:00AM
Mar-11-21 08:00AM
Mar-02-21 08:00AM
Feb-25-21 03:30PM
Feb-24-21 04:05PM
Feb-18-21 10:57AM
Feb-17-21 08:30AM
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.